Skip to main content
OpenTrials
Completed

NCT Number: NCT00178776

A Transtheoretical Model Group Therapy for Cocaine

The purpose of this study is to determine the feasibility and promise of a recently manualized group therapy based on the Transtheoretical Model for cocaine use disorders.

Completed

Looking for future studies?

Notify Me

Key information

Age range

18 year–65 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 1

Primary location

University of Texas Houston Mental Sciences Institute

Houston, Texas, 77030, United States

About this study

Cocaine use in the general population is a significant and costly problem. Novel and innovative interventions targeting cocaine abuse are needed. The Transtheoretical Model of behavior change (TTM) offers a comprehensive framework for understanding, measuring, and intervening in behavior change and provides a strong theoretical foundation upon which effective treatments for substance abuse can be developed. The proposed Stage 1 research will pilot test a novel and innovative behavioral group therapy for cocaine users based on the TTM. In Phase 1, investigators will modify the newly developed Group Treatment for Substance Abuse: A Stages-of-Change Therapy Manual (Velasquez, Maurer, Crouch & DiClemente, 2001) to specifically target cocaine abuse resulting in a twelve-session, group intervention and accompanying therapy manual based on the TTM stages and processes of change: six "early stage" sessions targeting the experiential processes of change, and six "later stage" sessions targeting the behavioral processes of change. Phase 2 will consist of a pilot trial to evaluate the TTM group therapy with cocaine abusing patients. A randomized, controlled, between groups design will be used in which cocaine abusers (N=80) are assigned to one of two group treatment conditions: TTM therapy or Education/Advice. Participants will be recruited from Houston and surrounding communities through the Substance Abuse Research Center at the University of Texas Health Science Center Mental Sciences Institute. We expect the delivery of the TTM therapy for cocaine users to be feasible and acceptable, and to produce significant patient improvement. Cocaine outcomes will be assessed via objective (urine and drug analysis) and self-report measures. This Stage I research will contribute important theoretical and empirical information concerning the promise of a new and innovative intervention for cocaine abusers, and will provide the basis for a larger efficacy trial.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

Inclusion criteria

Male and female adults (ages 18-65 years old), of any race, who meet DSM-IV criteria for cocaine abuse or dependence disorder will be recruited. In addition, eligible participants must be:

  • (1) judged to be in generally good physical and psychiatric health except for possible acute drug related problems;
  • (2) willing and able to participate in the 6-week, group outpatient treatment;
  • (3) able to provide the name of at least one person who can generally locate their whereabouts; and
  • (4) willing to be followed for 3 months after treatment ends.

Potential subjects with simple drug charges whose legal contacts are willing to forego data revelation will be included. Although cocaine dependence will be the primary drug for which patients are seeking treatment, we will not exclude participants who are abusing additional substances.

Exclusion criteria

Individuals will be ineligible for study participation based on the following criteria:

  • (1) current diagnosis of an Axis I psychiatric disorder other than cocaine dependence;
  • (2) current psychiatric symptoms requiring medication;
  • (3) severe medical, cognitive and /or psychiatric impairment that precludes cooperation with study protocol;
  • (4) substance withdrawal symptoms requiring medical attention;
  • (5) currently receiving other psychosocial therapy for substance abuse with the exception of AA, NA or CA;
  • (6) impending incarceration;
  • (7) inability to read, write, speak English;
  • (8) inability or unwillingness to participate in the 6-week, group outpatient treatment (e.g., halfway house or other aftercare program restrictions).

Treatment and study plan

Transtheoretical Model Group Therapy

Behavioral

Education & Advice

Behavioral

Primary outcomes

  1. Urinalysis indicating presence or absence of cocaine metabolites, used to calculate percent days abstinent, collected at intake, once weekly during the 6 week group treatment phase, at post-treatment, and 3 months.

Secondary outcomes

  1. Secondary Outcome Measures Related to Cocaine and other Drug Use:

  2. 1) Timeline Follow-Back (self-reported use / percent days

  3. abstinent)

  4. 2) Cocaine Craving Worksheet (self report)

  5. 3) Cocaine Negative Consequences Checklist (self report)

  6. 4) Addiction Severity Index (ASI; Interviewer Administered)

  7. 5) Blood Alcohol Breath (biological)

  8. 6) Substance Use Report (self report)

  9. Secondary Outcome Measures Related to Feasibility of the Group Therapy:

  10. 1) Participation / Attendance / Retention

  11. 2) MI Scale (Therapist Adherence)

  12. 3) Treatment Satisfaction Questionnaire

  13. 4) Group Therapy Alliance Scale

  14. 5) Group Atmosphere Scale

  15. 6) Therapist Treatment Evaluation

  16. Secondary Outcome Measures Related to Psychiatric Symptoms:

  17. 1) Beck Depression Inventory (BDI-II)

  18. 2) Brief Symptom Inventory (BSI)

  19. Secondary Outcomes Related to Functioning:

  20. 1) HIV Knowledge Questionnaire

  21. 2) Risk Behavior Assessment

  22. 3) SF-12

Sponsors and collaborators

Lead sponsor

National Institute on Drug Abuse (NIDA)

Nih

Collaborators

  • The University of Texas Health Science Center, Houston

Registry information

Important dates

Study start
2003
Primary completion
2006
Study completion
2007
First posted
Sep 15, 2005
Registry last updated
Jan 11, 2017

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.